Advertisement

Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa

  • Marcos A. González-LópezEmail author
  • Iosune Vilanova
  • Gonzalo Ocejo-Viñals
  • Rubén Arlegui
  • Iñigo Navarro
  • Sandra Guiral
  • Cristina Mata
  • M. Genma Pérez-Paredes
  • Virginia Portilla
  • Alfonso Corrales
  • M. Carmen González-Vela
  • Miguel A. González-Gay
  • Ricardo Blanco
  • José L. Hernández
Concise Communication
  • 26 Downloads

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with insulin resistance (IR), metabolic syndrome and increased cardiovascular risk. Adipokines are biologically active, pleotropic molecules which have been involved in the development of IR and in the pathogenesis of several chronic inflammatory conditions. The aim of the present study was to analyze serum concentrations of adiponectin, leptin, resistin and visfatin in patients with HS, and investigate their possible associations with IR, HS risk and disease severity. This case–control study enrolled 137 non-diabetic individuals (76 HS-patients and 61 age and sex-matched controls). Serum concentrations of adiponectin, leptin, resistin and visfatin, and the homeostasis model assessment of IR (HOMA-IR) were measured in all the participants. Serum adiponectin concentrations were found to be significantly lower, and leptin, resistin and visfatin levels were significantly higher in HS-patients than in controls. These differences remained significant even after adjusting for age, sex and body mass index, except for leptin. In a multivariate regression analysis, HOMA-IR was inversely correlated with adiponectin and positively associated with resistin levels. Furthermore, serum levels of resistin and visfatin were independently associated with HS risk. However, we found no association between serum levels of adipokines and HS severity. Our results suggest that reduced adiponectin and increased resistin serum levels may be surrogate biomarkers for IR in patients with HS. Moreover, resistin and visfatin might be independent risk factors for the development of HS.

Keywords

Hidradenitis suppurativa Adiponectin Leptin Resistin Visfatin Insulin resistance 

Notes

Funding

This study was funded through an unrestricted Grant provided by AbbVie.

Compliance with ethical standards

Conflict of interest

Dr. Marcos A. González López had consultation fees/participation in company sponsored speaker’s bureau from Abbvie. Dr. MA Gonzalez-Gay received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker ́s bureau from Pfizer, Lilly, Roche and Sanofi. Dr. R Blanco received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker ́s bureau from Abbvie, Pfizer, Roche, Bristol Myers, Janssen and MSD. The rest of the authors have no conflict of interest to declare regarding this paper.

Ethical protocol

The research protocol was approved by the Ethics Committee of Cantabria (Spain). All study procedures were performed in accordance with the ethical principles of the 1964 Declaration of Helsinki and written informed consent was obtained from all the subjects.

References

  1. 1.
    Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29(4):619–644CrossRefGoogle Scholar
  2. 2.
    Negus D, Ahn C, Huang W (2018) An update on the pathogenesis of hidradenitis suppurativa: implications for therapy. Expert Rev Clin Immunol 14(4):275–283CrossRefGoogle Scholar
  3. 3.
    Vossen ARJV, van der Zee HH, Prens EP (2018) Hidradenitis Suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol 14(9):2965CrossRefGoogle Scholar
  4. 4.
    Fimmel S, Zouboulis CC (2010) Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2(1):9–16CrossRefGoogle Scholar
  5. 5.
    Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I, Queiro R, Bassas-Vila J, Martorell A, García-Campayo J (2018) Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 32(1):129–144CrossRefGoogle Scholar
  6. 6.
    Pescitelli L, Ricceri F, Prignano F (2018) Hidradenitis suppurativa and associated diseases. G Ital Dermatol Venereol 153(3 Suppl 2):8–17PubMedGoogle Scholar
  7. 7.
    Vilanova I, Hernández JL, Mata C, Durán C, García-Unzueta MT, Portilla V, Fuentevilla P, Corrales A, González-Vela MC, González-Gay MA, Blanco R, González-López MA (2018) Insulin resistance in hidradenitis suppurativa: a case–control study. J Eur Acad Dermatol Venereol 32(5):820–824CrossRefGoogle Scholar
  8. 8.
    Phan K, Charlton O, Smith SD (2019) Hidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta-analysis. Clin Exp Dermatol 44(4):e126–e132CrossRefGoogle Scholar
  9. 9.
    Phan K, Charlton O, Smith SD (2019) Hidradenitis suppurativa and metabolic syndrome-systematic review and adjusted meta-analysis. Int J Dermatol.  https://doi.org/10.1111/ijd.14500 CrossRefPubMedGoogle Scholar
  10. 10.
    González-López MA, Hernández JL, Lacalle M, Mata C, López-Escobar M, López-Mejías R, Portilla V, Fuentevilla P, Corrales A, González-Vela MC, González-Gay MA, Blanco R (2016) Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa. J Am Acad Dermatol 75(2):329–335CrossRefGoogle Scholar
  11. 11.
    Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429–434CrossRefGoogle Scholar
  12. 12.
    Gremese E, Tolusso B, Gigante MR, Ferraccioli G (2014) Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). Front Immunol 11(5):576Google Scholar
  13. 13.
    Żelechowska P, Kozłowska E, Pastwińska J, Agier J, Brzezińska-Błaszczyk E (2018) Adipocytokine involvement in innate immune mechanisms. J Interferon Cytokine Res.  https://doi.org/10.1089/jir.2018.0102 CrossRefPubMedGoogle Scholar
  14. 14.
    Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115(5):911–919CrossRefGoogle Scholar
  15. 15.
    Francisco V, Ruiz-Fernández C, Pino J, Mera A, González-Gay MA, Gómez R, Lago F, Mobasheri A, Gualillo O (2019) Adipokines: linking metabolic syndrome, the immune system, and arthritic diseases. Biochem Pharmacol 165:196–206CrossRefGoogle Scholar
  16. 16.
    Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG (2017) Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology 233(5):378–389CrossRefGoogle Scholar
  17. 17.
    Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R, An J, Ma H (2017) Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget 9(1):1266–1278PubMedPubMedCentralGoogle Scholar
  18. 18.
    Dikbas O, Tosun M, Bes C, Tonuk SB, Aksehirli OY, Soy M (2016) Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. Int J Rheum Dis 19(7):672–677CrossRefGoogle Scholar
  19. 19.
    Malara A, Hughes R, Jennings L, Sweeney CM, Lynch M, Awdeh F, Timoney I, Tobin AM, Lynam-Loane K, Tobin L, Hogan A, O'Shea D, Kirby B (2018) Adipokines are dysregulated in patients with hidradenitis suppurativa. Br J Dermatol 178(3):792–793CrossRefGoogle Scholar
  20. 20.
    Akdogan N, Alli N, Uysal PI, Topcuoglu C, Candar T, Turhan T (2018) Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case-control study. Arch Dermatol Res 310(10):785–793CrossRefGoogle Scholar
  21. 21.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final report (2002). Circulation 106:3143–3421CrossRefGoogle Scholar
  22. 22.
    López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, Triana-Cubillos S (2014) The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig 18(1):37–45PubMedGoogle Scholar
  23. 23.
    Uslu S, Kebapçi N, Kara M, Bal C (2012) Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med 4(1):113–120CrossRefGoogle Scholar
  24. 24.
    Abella V, Scotece M, Conde J, Pino J, Gonzalez-Gay MA, Gómez-Reino JJ, Mera A, Lago F, Gómez R, Gualillo O (2017) Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol 13(2):100–109CrossRefGoogle Scholar
  25. 25.
    Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, Martin J, Dessein PH, Llorca J (2009) Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 27(2):222–228PubMedGoogle Scholar
  26. 26.
    Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Hernández JL, Llorca J, Gonzalez-Gay MA (2015) Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy. J Eur Acad Dermatol Venereol 29(10):1995–2001CrossRefGoogle Scholar
  27. 27.
    Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Blanco R, Pina T, González-Juanatey C, Llorca J, González-Gay MA (2014) Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis. Biomed Res Int 2014:860651PubMedPubMedCentralGoogle Scholar
  28. 28.
    Bannigida DM, Nayak SB (2018) Serum visfatin and adiponectin—markers in women with polycystic ovarian syndrome. Arch Physiol Biochem 13:1–4Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Marcos A. González-López
    • 1
    Email author
  • Iosune Vilanova
    • 1
  • Gonzalo Ocejo-Viñals
    • 2
  • Rubén Arlegui
    • 1
  • Iñigo Navarro
    • 1
  • Sandra Guiral
    • 2
  • Cristina Mata
    • 3
  • M. Genma Pérez-Paredes
    • 1
  • Virginia Portilla
    • 4
  • Alfonso Corrales
    • 4
  • M. Carmen González-Vela
    • 5
  • Miguel A. González-Gay
    • 4
  • Ricardo Blanco
    • 4
  • José L. Hernández
    • 6
  1. 1.Division of Dermatology, Hospital Universitario Marqués de ValdecillaUniversity of Cantabria, IDIVALSantanderSpain
  2. 2.Division of Immunology, Hospital Universitario Marqués de ValdecillaUniversity of Cantabria, IDIVALSantanderSpain
  3. 3.Division of RheumatologyHospital ComarcalLaredoSpain
  4. 4.Division of Rheumatology, Hospital Universitario Marqués de ValdecillaUniversity of Cantabria, IDIVALSantanderSpain
  5. 5.Division of Pathology, Hospital Universitario Marqués de ValdecillaUniversity of Cantabria, IDIVALSantanderSpain
  6. 6.Division of Internal Medicine, Hospital Universitario Marqués de ValdecillaUniversity of Cantabria, IDIVALSantanderSpain

Personalised recommendations